康普瑞汀脂质体体外抗乳腺癌拟态血管的作用

   澳门金沙

康普瑞汀脂质体外部情况抗胸脯癌仿制的容器的功能
刘汉1, 黄丹2, 郭阳2, 张烜2*
1. 常德职业技术学院,湖南 常德 415000;
2. 现在称Beijing分子制药业与新药递送体系医用生物学, 现在称Beijing 100191
In Vitro Anticancer Effect of Combretastatin A4 Liposomes in Destruction of Vascular Mimicry in Triple-Negative Breast Cancer Cells
LIU Han1, HUANG Dan2, GUO Yang2, ZHANG Xuan2*
1. Changde 度假的 Technical College, Changde 415000, China;
2. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences,Peking University Health Science Center, Beijing 100191, China

摘要 得分 考查康普瑞汀(combretastatin A4,CA4)脂质体(SSL-CA4)对外部情况仿照容器具有抵抗力(VASC) mimicry,虚拟机的功能。办法 选择CA4作为外形图案药物,构造SSL-CA4。MDA-MB-231胸脯癌细胞外形图案的屏风,SLS-CA4对MDA-MB-231增加操纵者功能的学习、挑毛病同盟对MDA-MB-231细胞的支配、MDA-MB-231细胞仿照容器的外部情况遇难船的残骸、3种因素在MDA-MB-231细胞射中靶子竞争功能。末后 SSL-CA4具有外部情况抗MDA-MB-231细胞外形的仿制的容器功能。裁定 SLS-CA4经过抗仿照血液V的功能形成抗果心功能。
关键词
康普瑞汀脂质体, 
MDA-MB-231细胞, 
仿制的容器, 
抗果心功能 
  
AbstractOBJECTIVE To investigate the potential anticancer effect of combretastatin A4 liposomes (SSL-CA4) in destruction of vascular mimicry (VM) in MDA-MB-231 breast cancer cells in vitro. METHODS The in vitro inhibitory effect and blocking wound-healing effect of SSL-CA4 were 考察。 The VM destruction of SSL-CA4 was evaluated in three dimensional matrigel culture model in MDA-MB-231 细胞。 The in vitro inhibitory test showed that the maxium inhibition ratio of SSL-CA4 on MDA-MB-231 cells was close to 50%. SSL-CA4 blocked the wound-healing of MDA-MB-231 cells, which was similar to free CA4. RESULTS SSL-CA4 could inhibit the formation of VM in vitro via inhibition on the VM channel indicators including 低氧绑架 factor (HIF-α), vascular 内皮钙黏卵白 (VE CAD), and matrix 金属肽酶 (MMP-2). The inhibition on indicators of SSL-CA4 was significantly higher than CA4 treatment groups (P<). CONCLUSION SSL-CA4 has significant anticancer activity via inhibition of VM in MDA-MB-231 cell 线。
Key words
combretastatin A4 liposomes
   MDA-MB-231 cell line
   vascular mimicry
   anticancer efficacy
  
收稿日期: 2017-07-06

    

基金帮助:国家重点根底学习整理973帮助定约雇用(2013CB932501)
新闻报告作者:
张烜,男,教 学习趋势:瞄准给药体系 Tel:(010)82805928 E-mail:xuanzhang@   
关于作者: 刘汉,男,教师 学习趋势:新药预备的打开;黄丹,女,硕士学习生 学习趋势:瞄准给药体系。Liu Han和黄丹是第一流的作者的合著者。
援用本文   
刘汉, 黄丹, 郭阳, 张。 康普瑞汀脂质体外部情况抗胸脯癌仿制的容器的功能[J]. 奇纳药学弹药库, 2018, 53(4): 278-282.

LIU Han, HUANG Dan, GUO Yang, ZHANG Xuan。 In Vitro Anticancer Effect of Combretastatin A4 Liposomes in Destruction of Vascular Mimicry in Triple-Negative Breast Cancer 细胞。 Chinese Pharmaceutical Journal, 2018, 53(4): 278-282.

联系在一起到本文  
     或     
[1] TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
[2] ORTIZ-RUIZ M J, ALVAREZ-FERNANDEZ S, PARROTT T, et al. Therapeutic potential of ERK5 targeting in triple negative breast 社会恶习[ J ] Oncotarget, 2014,5(22):11308-11318.

[3] BAUER K R, BROWN M, CRESS R D, et al. Descriptive analysis of estrogen receptor (ER)-否定词语, progesterone receptor (PR)-否定词语, and HER2否定词语 invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer 挂号处[j] Cancer, 2007,109(9):1721-1728.
[4] NAVRATIL J, FABIAN P, PALACOVA M, et al. Triple negative breast 社会恶习[ J ] Klin Onkol, 2015,28(6):405-415.

[5] LUAN Y Y, LIU Z M, ZHONG J Y, et al. Effect of grape seed proanthocyanidins on tumor vasculogenic mimicry in human triple-negative breast cancer 细胞[j] Asian Pac J Cancer Prev, 2015,16(2):531-535.
[6] LIU T, SUN B, ZHAO X, et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast 癌[ J ] J Cell Mol Med, 2013,17(1):116-122.
[7] ZHANG S, ZHANG D, SUN B. Vasculogenic mimicry: current status and future 预期[ J ] Cancer Lett, 2007,254(2):157-164.
[8] ZHANG D, SUN B, ZHAO X, et al. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast 社会恶习[ J ] Mol Cancer, 2014,13:207.

[9] LIU T J, SUN B C, ZHAO X L, et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast 社会恶习[ J ] Oncogene, 2013,32(5):544-553.

[10] KIRSCHMANN D A, SEFTOR E A, HARDY K M, et al. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic 欣赏[ J ] Clin Cancer Res, 2012,18(10):2726-2732.
[11] WEST C M, PRICE P. Combretastatin A4 汽水〔J〕 Anticancer Drugs, 2004,15(3):179-187.
[12] GRIGGS J, METCALFE J C, HESKETH R. Targeting tumour vasculature: the development of combretastatin A4[J] Lancet Oncol, 2001,2(2):82-87.
[13] HUANG D, ZHANG S, ZHONG T, et al. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving 抗胶质瘤 医疗[ J ] Oncotarget, 2016,7(28):43616-43628.

[14] ZHONG T, YAO X, ZHANG S, et al. A self-assembling nanomedicine of conjugated linoleic acid-paclitaxel conjugate (CLA-PTX) with higher drug loading and carrier-free characteristic [J]. Sci Rep, 2016, 6:36614.

[15] HUANG Y, CHEN X M, ZHAO B X, et al. Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo [J]. AAPS Pharm Sci Tech, 2010, 11(2):752-759.
[16] CAO Z, BAO M, MIELE L, et al. Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and Meta剖析[J] Eur J Cancer, 2013,49(18):3914-3923.
[17] LIU T J, SUN B C, ZHAO X L, et al. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast 社会恶习[ J ] Oncogene, 2013,32(5):544-553.
[18] ZENG F, JU R J, LIU L, et al. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast 社会恶习[ J ] Oncotarget, 2015,6(34):36625-36642.

[19] QIAO L, LIANG N, ZHANG J, et al. Advanced research on vasculogenic mimicry in 社会恶习[ J ] J Cell Mol Med, 2015,19(2):315-326.
[20] PAULIS Y W, SOETEKOUW P M, VERHEUL H M, et al. Signalling pathways in vasculogenic 仿制的[ J ] 比奇姆 Biophys Acta, 2010,1806(1):18-28.

[21] LIU X M, ZHANG Q P, MU Y G, et al. Clinical significance of vasculogenic mimicry in human 胶质瘤[j] J Neurooncol, 2011,105(2):173-179.
[22] 斯林格兰 M, GUCHELAAR H J, GELDERBLOM H. Liposomal drug formulations in cancer therapy: 15 years along the 途径[ J ] Drug 迪斯科 Today, 2012,17(3-4):160-166.
[23] MARTINA M S, NICOLAS V, WILHELM C, et al. The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and 巨噬细胞[j] Biomaterials, 2007,28(28):4143-4153.
[24] XIONG X B, HUANG Y, LU W L, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD 仿制的[ J ] J Controlled Release, 2005,107(2):262-275.
[1] 潘东生, 沈连忠, 盖文琳, 周小冰, 下风波。 抗盖上增加因素感受器全人单克隆对称体Ranti-HER的抗果心药理功能学习[J]. 奇纳药学弹药库, 2016, 51(21): 1839-1847.
[2] 秦峥, 邓振雪, 刘希, 谢玉婷, 小宇齐, 徐翠岭, 郑尚时节, 孙丽欣。 16孕烯醇酮脂质体的体内外抗果心功能[J]. 奇纳药学弹药库, 2015, 50(14): 1202-1207.
[3] 应雪,柳岩方,袁苗苗,朱佳,汤卉。 表柔比星白藜芦醇脂质体的准备及其抗果心主动语态[J]. 奇纳药学弹药库, 2014, 49(14): 1233-1239.
[4] 赵永之星 赵阳 张振中 张雪肖 孙倩。 冬凌草甲素/胆甾烯酮酰基壳多糖共多聚体微胶粒的准备及T[J]. 奇纳药学弹药库, 2011, 46(13): 1015-1019.
[5] 戴志凯 程是一位好先生。 酮使严重抗果心学习进展[J]. 奇纳药学弹药库, 2010, 45(22): 1701-1703.
[6] 上帝作证!天呀!啊呀!胡安 李亮 赵春燕 王宇峰 李彤董 甄永素。 单链对称体与利达霉菌素遗传工程的抗果心功能[J]. 奇纳药学弹药库, 2010, 45(11): 808-813.
[7] 石爱欣;傅德星。 酪氨酸致活酶操纵者剂的学习进展[J]. 奇纳药学弹药库, 2008, 43(14): 1045-1049.
[8] 他是吴;灵筱。 小分子EGFR酪氨酸致活酶操纵者剂的学习进展[J]. 奇纳药学弹药库, 2007, 42(22): 1685-1688.
[9] 谢冰芬;冯公侃;河;朱孝峰;王一;邓蓉;刘宗潮;黄志纾;吴海强;古练权. 萘醌诱导剂(Akanin)SyunZ-4的抗果心功能[J]. 奇纳药学弹药库, 2007, 42(18): 1384-1388.
[10] 吉宇彬;高世永。 海嘧啶外部情况及外部情况抗果心功能的学习[J]. 奇纳药学弹药库, 2005, 39(23): 1788-1793.
[11] 张青;唐晓江;胡志一;刘红霞。 藻内酯及其中间体的药物学学习[J]. 奇纳药学弹药库, 2003, 38(10): 766-768.
[12] 孙云传;赵欢宇;陈晓光。 法呢基移换酶操纵者剂CA-7的抗果心功能[J]. 奇纳药学弹药库, 2003, 38(08): 587-590.
[13] 郭俊华;徐卓丽;宋三泰;梁月沁;吴德正。 程序制导E对顺铂毒性的防护装置功能及其对果心的防护装置功能[J]. 奇纳药学弹药库, 1994, 29(04): 207-211.

没有评论

发表评论

电子邮件地址不会被公开。 必填项已用*标注